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Background and Aims
Left ventricular systolic dysfunction (LVSD) represents a
risk factor for the development of low cardiac output syn-
drome (LCOS) resulting in a high mortality in patients
undergoing cardiac surgery, Levosimendan is a drug with
inotropic, vasodilatory and organ-protective properties,
often used in heart failure and low cardiac output patients.
We study the effects of preoperative levosimendan
administration (PLA) in patients with LVSD undergoing
elective cardiac surgery on LCOS development and
other secondary post-surgery outcomes
Methods
We retrospectively studied a cohort of patients with
LVEF ≥ 45% undergoing elective cardiac surgery from
January 2006 to December 2013. Patients who received
PLA (infusion of 0.05 to 0.2 mcg /kg /min for 24 hours
without loading dose) - (Group I) within 72 hours prior
to surgery were compared with those who did not receive
it (Group II). Demographic, clinical, hemodynamic,
operative characteristics and postoperative outcome were
analyzed. PLCO was consider as cardiac index lower than
2.2 l/min/m2, without low blood volumen.
Results
146 patients with LVSD were included. 80% were male;
mean age 66 ± 9.7 years; LVEF 36 ± 5%; and Euroscore
8.7 ± 8.6 were studied. Group I included 13 and Group
II 123 patients.
Among both groups there were no significant differ-
ences in age, sex, cardiovascular risk factors, preoperative
functional class, LVEF and operative characteristics.
Group I patients had a lower incidence of LCOS (7.7 vs
43.6%; p = 0.012); higher cardiac index (3.2 ± 0.7 vs 2.7 ±
0.8 L/min/m2; p = 0.02); lower troponin I peak levels of (1.9
± 1.8 ng/mL vs 10.4 ± 32; p = 0.02); lower creatinine peak
levels (0.98 ± 0.4 vs 1.3 ± 0.7 mg/dL; p = 0.03 and shorter
mechanical ventilation (4 [2-7] vs 6 [5-19] h; p 0.007)). They
needed lower maximum dose of dobutamine (1.4 ± 1.9 vs
4.7 ± 5.3 mcg/kg/min; p = 0.016). De novo atrial fibrillation
incidence was similar in both groups (30 vs 32%; p = NS).
Group I patients had a lower but not significantly post-
operative hospital stay (7 [6-10] vs 9 [7-17] days; P = 0.08).
There was no differences in mortality at 30 days (0 vs 7.5%;
P = NS). After adjusting for preoperative LVEF and NYHA,
patients in Group I showed less risk of LCOS development
(OR: 0.11; 95% CI [0.01-0.85]; p = 0.005).
Conclusions
Preoperative administration of Levosimendan reduces
the incidence of LCOS and exerts beneficial effects on
myocardial and renal preservation in high-risk patients
with LVSD undergoing elective cardiac surgery.
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